vimarsana.com
Home
Live Updates
New data presented at ASH 2021 highlight potential of Blenre
New data presented at ASH 2021 highlight potential of Blenre
New data presented at ASH 2021 highlight potential of Blenrep (belantamab mafodotin-blmf) in combination with standard of care therapies in earlier lines of multiple myeloma treatment
/PRNewswire/ -- GlaxoSmithKline (GSK) plc today announced new data from the DREAMM-9 (DRiving Excellence in Approaches to Multiple Myeloma) phase I trial and...
Related Keywords
United States ,
Canada ,
South Korea ,
Philadelphia ,
Pennsylvania ,
Middlesex ,
United Kingdom General ,
United Kingdom ,
Washington ,
Brentford ,
Hounslow ,
London ,
City Of ,
Greece ,
Canadian ,
Han ,
American ,
Hesham Abdullah ,
Madeleine Breckon ,
Saadz Usmani ,
Kathleen Quinn ,
Josh Williams ,
Jeff Mclaughlin ,
Sonya Ghobrial ,
Mick Readey ,
Prnewswire Glaxosmithkline ,
Tim Foley ,
James Dodwell ,
Kristen Neese ,
Nick Stone ,
Glaxosmithkline ,
Kyowa Kirin Group ,
Global Head Of Oncology Development ,
Myeloma Service ,
Company Annual Report On Form ,
American Society Of Hematology ,
Biowa Inc ,
Hellenic Society Of Hematology ,
Canadian Myeloma Research Group ,
Memorial Sloan Kettering Cancer Center ,
Multiple Myeloma ,
American Society ,
Annual Meeting ,
Global Head ,
Oncology Development ,
Hellenic Society ,
Kyowa Kirin ,
Risk Evaluation ,
Mitigation Strategy ,
Snellen Visual Acuity ,
Acuity Changes ,
Patient Instruction ,
Related Reactions ,
Fetal Toxicity ,
Reproductive Potential ,
Hepatic Impairment ,
Prescribing Information ,
Medication Guide ,
Annual Report ,
West Road ,
Cancer Journal ,
Accessed October ,
Glaxosmithkline Plc ,